|
| Tuesday, 20 September 2022, 23:50 HKT/SGT | |
| |
|
|
Gaithersburg, MD, USA and Suzhou BioBay, China, Sept 20, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead(TM) platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.
Presentation Details
Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics Time/Date: 15:20 GMT on Wednesday, September 21, 2022 Presentation Topics: -- Creating novel siRNA constructs for cancer treatment -- Introduction to Sirnaomics' polypeptide nanoparticle delivery system (PNP-IT) -- Introduction to STP705, Sirnaomics' lead oncology siRNA therapeutic targeting TGF-beta1/COX-2 -- Discussion of novel siRNA therapeutics targeting other oncology indications
Presentation Title: GalAhead(TM) Therapeutic Platform and Programs Presenter: Dr. Jack Wei, Senior Director, Sirnaomics Time/Date: 16:30 GMT on Thursday, September 22, 2022 Presentation Topics: -- Introduction to GalAhead(TM), Sirnaomics' GalNAc-RNAi therapeutic platform -- Miniaturized RNAi (mxRNA) as a key technological component of the platform -- Validation of technology in vivo and in vitro -- Progress report on GalAhead(TM)-based programs
For more information about Sirnaomics' presentation, please visit the event website at https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery.
About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.
CONTACT: Investor Relations: Nigel Yip, MBA Chief Financial Officer, China, Sirnaomics Email: NigelYip@sirnaomics.com
US Media Contact: Alexis Feinberg Tel: +1 203 939 2225 Email: Alexis.Feinberg@westwicke.com
Asia Media Contact: Bunny Lee Tel: +852 3150 6707 Email: sirnaomics.hk@pordahavas.com
Topic: Press release summary
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Graphene quantum dots show promise in targeting Parkinson's-related protein clumping
May 20, 2026 17:00 HKT/SGT
|
|
|
CTF Life Launches Hong Kong's First Indexed Universal Life Insurance Plan Linked to BNP Paribas' Indices
May 20, 2026 16:11 HKT/SGT
|
|
|
Heads of State/Government, Ministers, and Senior Officials from 30 Countries to Convene in Tokyo for the Island States Ocean Summit
Wednesday, May 20, 2026 4:00:00 PM
|
|
|
Trusco Nakayama and Fujitsu accelerate personnel transfer decision-making process with data and AI
Wednesday, May 20, 2026 12:50:00 PM
|
|
|
Xero Launches Lite Plan in the Philippines to Help Filipino Small Businesses Master Their Finances
May 20, 2026 10:50 HKT/SGT
|
|
|
Xero Launches Lite Plan in Indonesia to Help Indonesian Small Businesses Master Their Finances
May 20, 2026 10:50 HKT/SGT
|
|
|
Hitachi announces strategic partnership with Anthropic to strengthen "Lumada 3.0" through frontier AI
Tuesday, May 19, 2026 10:09:00 PM
|
|
|
AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform
May 19, 2026 22:00 HKT/SGT
|
|
|
GMG's THERMAL-XR(R) to be Applied Exclusively & Distributed to Global Oil and Gas/LNG Industry with Curran International
May 19, 2026 20:29 HKT/SGT
|
|
|
Kincora Receives Option Payment for Divestment of Mongolian Assets
May 19, 2026 17:59 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
 |
 |
 |
|
 |
|